
FDA approves pralsetinib for RET-altered thyroid cancers
On December 1, 2020, the Food and Drug Administration approved pralsetinib for adult and paediatric…
On December 1, 2020, the Food and Drug Administration approved pralsetinib for adult and paediatric…
The Food and Drug Administration granted accelerated approval to pralsetinib for adult patients with metastatic…
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…